Senior Research Scientist - Proteomics

Sapient launches gclp-compliant workflows to expand support for clinical biomarker testing. These designated workflows meet enhanced quality and traceability standards required of assay data generated for clinical trials, including those supp. Sept. 22, 2026 Press Contacts Carla Nieser 8582907010 SAN DIEGO - September 22, 2026 - San Diego, CA - Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched designated workflows that comply with the World Health Organization's Good Clinical Laboratory Practice (GCLP) guidance, enabling the company to expand its services for clients requiring assays to support active clinical trials - including for primary and secondary endpoints. GCLP is an international quality standard and framework for laboratories that analyze human-derived samples from clinical trials, requiring enhanced controls for traceability, assay precision, documentation, and data integrity to produce reliable, accurate, and auditable results. Sapient has validated the instrumentation, quality management system (QMS), and laboratory information system (LIMS) used in its GCLP-compliant workflows to these standards, enabling delivery of audit-ready data for GCLP-designated studies in line with the expectations of global regulatory authorities. This documented quality framework is backed by deep QA and regulatory expertise within the Sapient team, comprising quality, operational, and scientific leaders who bring decades of combined experience supporting regulated studies for pharma and biotech sponsors. "GCLP governs the quality of assay data used to inform the most consequential decisions clinical trial sponsors are making about dose escalation, safety, and efficacy," said Jessica Weant, Director of Operations at Sapient. "Our clients can trust that we follow stringent practices for studies requiring GCLP compliance, to ensure the right procedure is followed, the right method is implemented, and the right records are documented, every time - equipping them with reliable, decision-grade data to act upon. It also now gives us the ability to develop targeted assays to measure primary and secondary endpoints, meaning clients can partner with Sapient for everything from exploratory analyses to late-stage trials." "It was important for us to expand our validated laboratory infrastructure so that clients can translate targets and biomarkers that we've helped them discover into targeted, regulated assays without having to move labs," said Jonathan Usuka, PhD, MBA, Chief Executive Officer at Sapient. "Establishing GCLP-compliant workflows also reflects our commitment to quality and the rigor with which we conduct every analysis. Many of the validated systems and processes used for our GCLP-designated analyses are shared by our research-use-only workflows, so customers benefit from robust quality frameworks no matter the phase we are partnering in." Sapient leverages its Thermo Stellar mass spectrometry platform for regulated assay work and can develop targeted assays under GCLP for any protein in its 12,000+ protein menu or through custom assay development. Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development. Utilizing cutting-edge, high-throughput mass spectrometry and biocomputational frameworks, Sapient enables comprehensive biomarker-phenotype mapping across thousands of biosamples for discovery of robust protein, metabolite, and lipid biomarkers, drug targets, and clinical signatures of drug response. The company's DynamiQ(TM) Insights Engine - a longitudinal molecular-clinical database collected from tens of thousands of human samples - enables rapid drug target identification, biomarker discovery and validation, and translational and clinical insights across all stages of drug development. For more information, visit sapient.bio.

Sapient launches DynamiQ Normal Human Tissue Proteomics Atlas. DynamiQ proteomics atlas maps protein expression across normal tissues to improve target prioritisation and safety assessment 16 Jun 2026 Product news. Sapient has launched the DynamiQ(TM) Normal Human Tissue Proteomics Atlas, a comprehensive reference map of protein expression, signaling activity, cell surface accessibility, immune biology, and resistance pathways across more than 12,000 proteins in diverse normal human tissues. The atlas enables drug development teams to systematically evaluate where therapeutic targets are expressed in normal human organs, quantify expression relative to tumor or diseased tissue, and identify organs at risk for on-target, off-tissue toxicity, supporting safer and more effective target selection decisions. Comprehensive proteomics atlas of normal human tissue biology. The DynamiQ Normal Human Tissue Proteomics Atlas provides drug developers with a proteome-wide view of normal human biology across more than 15 tissue types, including heart, liver, lung, kidney, and other primary organs commonly associated with dose-limiting toxicities. By enabling direct queries of target protein expression across these tissues, the atlas helps teams quantify tumor-to-normal expression ratios and rank-order candidate targets based on their potential therapeutic index. Beyond expression levels, the atlas incorporates baseline signaling, immune, and resistance pathway data to reveal organ-level vulnerabilities and potential immune-related adverse events. This integrated view of protein abundance, activation state, and biological context is designed to support proactive evaluation of safety liabilities before programs advance into clinical development. By integrating multiple proteomics modalities, the atlas offers a unified framework for understanding how therapeutic targets behave in normal human tissues, helping teams anticipate safety risks and refine their development strategies. Multi-dimensional proteomics profiling across 12,000+ proteins. Sapient uses its mass spectrometry-based proteomics platform to profile each normal human tissue across multiple biological dimensions: * Global protein expression across more than 12,000 protein groups via DiscoverySeek(TM) * Cell surface protein expression via SurfaceSeek(TM) * Phosphorylation-driven signaling pathway activity via SignalingSeek(TM) * Immune cell composition and activation states via ImmuneSeek(TM) * Baseline survival and stress response pathways via ResistanceSeek(TM) Through this comprehensive proteome-wide characterization, the DynamiQ Normal Human Tissue Proteomics Atlas reduces reliance on indirect proxy measurements of protein levels, such as RNA expression databases or single-cell RNA sequencing data. Instead, it delivers direct and diverse protein quantification to inform target selection, safety assessment, and translational strategy. Enabling earlier, data-driven safety and target selection decisions. By providing a detailed map of protein expression and activity in normal tissues, the DynamiQ Normal Human Tissue Proteomics Atlas allows researchers to identify organs at risk for toxicity, evaluate potential immune-related adverse events, and prioritize targets with more favorable safety profiles. This supports more informed decision-making from early discovery through to clinical development. Flexible access models for biopharma and translational research teams. The DynamiQ Normal Human Tissue Proteomics Atlas is available through flexible data licensing and proteomics services models. Options include data access for specific targets of interest, integration of atlas data with internal workflows, and custom proteomics studies using client-provided samples. These access models are designed to support a wide range of applications, from early-stage target discovery and validation to IND-enabling safety studies and clinical development programs. "This atlas does not simply catalog which proteins are present in normal tissues - it reveals how proteins are regulated, activated, and organized across normal human biology," said Dr. Mo Jain, Founder and Chief Scientific Officer at Sapient. "Unlike transcriptomic databases or low-plex immunohistochemistry, we are delivering direct and diverse protein measurements across the proteome - encompassing abundance, surface accessibility, signaling state, immune context, and resistance pathway biology - as a comprehensive reference framework that can be applied from early discovery to target selection, IND-enabling programs, and clinical development." Want the latest science news straight to your inbox? Become a SelectScience member for free today>>. Frequently asked questions. How does Sapient's DynamiQ Normal Human Tissue Proteomics Atlas support safer drug development? The DynamiQ Normal Human Tissue Proteomics Atlas enables drug development teams to systematically evaluate where therapeutic targets are expressed in normal human organs, quantify tumor-to-normal expression ratios, and identify organs at risk for on-target, off-tissue toxicity. This proteome-wide view supports more informed target selection and safety decisions from early discovery through clinical development. What proteomics modalities power the DynamiQ Normal Human Tissue Proteomics Atlas? Sapient uses a mass spectrometry-based proteomics platform to profile normal human tissues across multiple dimensions: DiscoverySeek(TM) for global protein expression, SurfaceSeek(TM) for cell surface proteins, SignalingSeek(TM) for phosphorylation-driven signaling, ImmuneSeek(TM) for immune cell composition and activation, and ResistanceSeek(TM) for baseline survival and stress response pathways. How can biopharma teams access the DynamiQ Normal Human Tissue Proteomics Atlas for translational research? The DynamiQ Normal Human Tissue Proteomics Atlas is available through flexible data licensing and proteomics services. Biopharma and translational research teams can license data for specific targets, integrate atlas data with internal workflows, or commission custom proteomics studies using client-provided samples, supporting applications from target discovery to IND-enabling safety and clinical development.